Animalcare (ANCR) AI Stock Analysis

• Market Cap: £172.47M
• Dividend Yield: 2%
• Average Volume (3M): 41.30K
• Price to Earnings (P/E): 32.0
• Beta (1Y): 0.23
• Revenue Growth: -0.17%
• EPS Growth: 592.46%
• Country: UK
• Employees: 226
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.40
• Shares Outstanding: 68,989,075
• 10 Day Avg. Volume: 55,380
• 30 Day Avg. Volume: 41,298
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £284.00
• Price Target Upside: 13.60% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 65 Neutral
• Price Target: 284.00p ▲(13.60% Upside)

Animalcare's overall stock score reflects strong corporate events and financial stability, offset by bearish technical indicators and high valuation concerns. Strategic expansions and acquisitions bolster future growth potential, but technical analysis suggests caution in the short term.

Positive Factors

Financial Stability

The company's strong equity ratio and low leverage indicate robust financial health, reducing risk and providing a solid foundation for future growth.

Cash Flow Generation

Strong cash flow generation enhances financial flexibility, enabling the company to invest in growth opportunities and manage liabilities effectively.

Profitability Improvement

Improved return on equity reflects better profitability and efficient use of shareholder funds, supporting long-term value creation.

Negative Factors

Revenue Contraction

A decline in revenue growth suggests challenges in expanding market share, potentially impacting long-term competitive positioning.

Rising Liabilities

Growing liabilities may strain financial resources and limit strategic flexibility, necessitating careful management to avoid long-term risks.

Negative Revenue Growth

Negative revenue growth highlights difficulties in market expansion, which could hinder the company's ability to capitalize on industry opportunities.

Animalcare Business Overview & Revenue Model

Company Description

Animalcare Group plc engages in the development, sale, and distribution of licensed veterinary pharmaceuticals and identification products, and services for companion and production animals, and equine veterinary markets. It is also involved in the wholesale and marketing of veterinary pharmaceuticals. The company serves customers in Belgium, the Netherlands, the United Kingdom, Germany, Spain, Italy, Portugal, other European countries, Asia, the Middle East, Africa, and internationally. Animalcare Group plc was incorporated in 1972 and is based in York, the United Kingdom.

How the Company Makes Money

Animalcare generates revenue through multiple streams, primarily from the sale of veterinary pharmaceuticals and healthcare products. Key revenue sources include the direct sale of prescription medications, over-the-counter products, and vaccines for both companion animals and livestock. The company also benefits from recurring revenue through a range of service agreements and partnerships with veterinary clinics and animal health organizations, which enhance its market reach. Additionally, Animalcare invests in research and development to create new products, thereby expanding its offering and driving future revenue growth. Strategic collaborations with veterinary professionals and industry stakeholders further contribute to its earnings by ensuring a continuous demand for its innovative solutions.

Animalcare Financial Statement Overview

Summary

Animalcare demonstrates strong financial stability with a healthy equity ratio and low debt-to-equity ratio. The company has improved its net profit margin and return on equity, despite a slight revenue contraction. Cash flow generation remains robust, supporting operational strategies, but rising liabilities need attention.

Income Statement

Animalcare has demonstrated stable revenue with a slight decrease in 2024. The gross profit margin remains strong at around 45.9% in 2024, reflecting efficient production. The net profit margin has significantly improved from previous years, reaching 43.4% in 2024, due to increased net income influenced by effective cost management. However, the revenue growth rate is negative over the past year, indicating a potential challenge in expanding market share.

Balance Sheet

The balance sheet shows a healthy equity ratio of 71.3% in 2024, indicating strong financial stability. The debt-to-equity ratio is low at 0.20, reflecting minimal leverage and low financial risk. Return on equity improved drastically to 28.4% in 2024, demonstrating enhanced profitability. However, the increase in total liabilities over the years could pose future risks if not managed effectively.

Cash Flow

Animalcare's cash flow statements reveal consistent free cash flow generation, with a growth rate of 51.7% from 2023 to 2024, supporting financial flexibility. The operating cash flow to net income ratio is robust at 0.37, indicating good cash conversion. However, the free cash flow to net income ratio is slightly lower at 0.36, suggesting some inefficiencies in cash utilization relative to net income.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	74.23M	74.35M	71.62M	74.02M	70.49M
Gross Profit	34.06M	43.35M	40.66M	39.42M	36.56M
EBITDA	13.43M	12.23M	11.04M	10.15M	10.30M
Net Income	32.22M	1.20M	1.97M	-77.00K	234.00K
Balance Sheet
Total Assets	158.81M	106.79M	118.24M	110.00M	124.44M
Cash, Cash Equivalents and Short-Term Investments	11.71M	4.64M	6.04M	5.63M	5.26M
Total Debt	23.16M	5.88M	11.44M	10.96M	18.88M
Total Liabilities	45.50M	28.90M	39.26M	31.20M	42.84M
Stockholders Equity	113.31M	77.89M	78.99M	78.80M	81.59M
Cash Flow
Free Cash Flow	11.72M	7.73M	6.48M	10.81M	8.68M
Operating Cash Flow	11.93M	10.28M	9.43M	14.02M	11.12M
Investing Cash Flow	-34.85M	-2.86M	-3.12M	-2.96M	-2.91M
Financing Cash Flow	32.53M	-8.95M	-5.70M	-10.96M	-8.86M

Animalcare Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 250.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:ANCR, the sentiment is Negative. The current price of 250 is below the 20-day moving average (MA) of 251.95, below the 50-day MA of 262.04, and above the 200-day MA of 249.70, indicating a neutral trend. The MACD of -3.61 indicates Negative momentum. The RSI at 33.10 is Neutral, neither overbought nor oversold. The STOCH value of 70.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:ANCR.

Animalcare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HIK	70 Outperform	3.62B	12.69	15.54%	3.87%	3.73%	27.13%
EAH	69 Neutral	66.74M	39.56	1.97%	―	-10.99%	60.65%
ANCR	65 Neutral	£172.47M	32.01	5.04%	2.00%	-0.17%	592.46%
AGY	56 Neutral	395.61M	-11.07	―	―	4.50%	74.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Animalcare Corporate Events

Animalcare Group Reports Strong H1 Revenue Growth Amid Strategic Expansion

Animalcare Group reported an 18.5% increase in H1 revenue, driven by strong performance from its newly acquired Australian equine business, Randlab, and growth in key products like Daxocox and Plaqtiv+. Despite challenges such as currency translation impacts and reduced sales of Conofite due to regulatory changes, the company remains optimistic about its strategic growth initiatives, including new product launches and international expansion, which are expected to enhance its market position and profitability.

The most recent analyst rating on (GB:ANCR) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.

Animalcare Expands into Asia-Pacific with Strategic Stake in InVetro

Animalcare Group plc has acquired a 25% equity stake in InVetro Pty Ltd, an Australian-based Companion Animal health business, for A$3 million. This strategic investment is part of Animalcare’s geographic expansion strategy, aiming to establish a presence in the fast-growing Companion Animal health market in Australia and potentially other Asia-Pacific territories. The investment will enable InVetro to scale its commercial operations, expand its product portfolio, and develop new products. Animalcare’s long-term goal is to build a Companion Animal business in the region with revenues of A$20-25 million. The partnership provides Animalcare with immediate market access, leveraging InVetro’s local expertise and regulatory capabilities, and sets the stage for future collaboration and increased ownership.

The most recent analyst rating on (GB:ANCR) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.

Animalcare Group plc Successfully Passes All Resolutions at 2025 AGM

Animalcare Group plc announced that all resolutions proposed at its 2025 Annual General Meeting were approved. The resolutions included the receipt of audited accounts, declaration of a final dividend, re-election of directors, and authorization for share allotment and purchase. This outcome reflects strong shareholder support and positions the company to continue its strategic initiatives and maintain its market presence.

The most recent analyst rating on (GB:ANCR) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.

Animalcare Group Announces New Share Issuance Under Incentive Plan

Animalcare Group plc has announced the exercise of options under its Long Term Incentive Plan, resulting in the issuance of 4,157 new ordinary shares. These shares will commence trading on AIM on 4 June 2025 and will be fully paid, ranking equally with existing shares. Following this issuance, the total number of shares with voting rights will be 68,989,072, providing a new denominator for shareholders to calculate their interests under the FCA’s rules.

The most recent analyst rating on (GB:ANCR) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.

Animalcare Group Announces New Share Issuance Following Option Exercise

Animalcare Group plc, an international animal health business, announced the exercise of options under its Long Term Incentive Plan, resulting in the issuance of 4,157 new ordinary shares. These shares will be admitted to trading on AIM on June 4, 2025, and will carry the same rights as existing shares, including voting rights. This issuance increases the total number of shares with voting rights to 68,989,072, impacting shareholder calculations under the FCA’s Disclosure and Transparency Rules.

The most recent analyst rating on (GB:ANCR) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.

Animalcare Group PLC Announces Change in Major Holdings

Animalcare Group PLC has announced a change in its major holdings, with Harwood Capital LLP adjusting its voting rights in the company. The notification indicates that Harwood Capital LLP’s voting rights have decreased from 10.232840% to 9.929000%, reflecting a slight reduction in their stake. This adjustment in holdings could influence the company’s governance and decision-making processes, potentially impacting its strategic direction and stakeholder interests.

The most recent analyst rating on (GB:ANCR) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.

Animalcare Group Releases 2024 Annual Report and Announces 2025 AGM

Animalcare Group plc has published its 2024 Annual Report and Financial Statements, along with the Notice of its 2025 Annual General Meeting. The AGM is scheduled for 10 June 2024 in London. This release highlights the company’s commitment to transparency and shareholder engagement, potentially impacting its market positioning and stakeholder relations positively.

The most recent analyst rating on (GB:ANCR) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.